| Company | Drug | Trial Result | |
|---|---|---|---|
| *AnaptysBio (ANAB) | Imsidolimab for Dermatology | Phase II GALLOP | |
| *Sage (SAGE) / Biogen | SAGE-217 for Major Depressive Disorder | Phase III WATERFALL | |
| *Imara (IMRA) / Lundbeck | IMR-687 for Sickle Cell Anemia | Phase IIb Ardent | |
| *Vertex (VRTX) | VX-147 for Focal Segmental Glomerulosclerosis | Phase II | |
| *Xenon (XENE) | XEN1101 for Partial Seizures (Epilepsy) | Phase IIb - X-TOLE | |
| *SpringWorks (SWTX) | Nirogacestat for Desmoid Tumors/Aggressive Fibromatosis | Phase III - DeFi | |
| *Sanofi (SNY) (Principia) | Rilzabrutinib (PRN1008) for Pemphigus Vulgaris | Phase III PEGASUS | |
| *Galera (GRTX) | Avasopasem (GC4419) for Mucositis | Phase III ROMAN | |
| *Summit Therapeutics (SMMT)/ Eurofarma | Ridinilazole for CDAD/CDI | Phase III Ri-CoDIFy 1 and 2 | |
| *Appellis | Pegcetacoplan for Dry AMD / Geographic Atrophy | Phase III DERBY | |
| Karyopharm Therapeutics | Xpovio | Phase III SIENDO | |
| Allakos Inc. | AK002 | Phase II/III KRYPTOS | |
| ImmunoGen | Mirvetuximab | Phase III SORAYA | |
| ObsEva SA | Linzagolix | Phase III EDELWEISS | |
| Ayala Pharmaceuticals | AL101 | Phase II TENACITY | |
| Biohaven Pharmaceutical | Troriluzole | Phase III SARA | |
| AbbVie | Cariprazine | Phase III in MDD (2 Trials) | |
| ACADIA Pharmaceuticals | Trofinetide | Phase III LAVENDER | |
| Bristol-Myers Squibb/Regenacy | Ricolinostat | Phase II | |
| Aeglea | Pegzilarginase | Phase III PEACE | |
| Novartis | Secukinumab | Phase III SUNSHINE/SUNRISE | IL-17 |
| Cortexyme | COR288 | Phase II/III GAIN | Lysine Gingipain (Protease) |
| Anavex Life Sciences Corp. | ANAVEX 2-73 | Phase II/III AVATAR | Sigma-1 and muscarinic receptors |
| Tonix Pharmaceuticals Holding Corp. | Tonmya | Phase III RALLY | Serotonin-2A (5-HT2A) receptor, Alpha-1-adrenergic receptor, Histamine-1 receptor |
| Angion Biomedica | ANG-3777 | Phase III GIFT | Hepatocyte Growth Factor Receptor |
| Stealth BioTherapeutics Inc. | Elamipretide (Systemic Delivery) | Phase II RECLAIM-2 | Cardiolipin |
Do you have a specific trial you’d like Diviner to forecast? Let us know!
On June 30th, Diviner and Molecular Health unveiled their predictions for the results of the trials shown with an asterisk. Watch the recording of the event.
Register here for a deck on the trials we forecasted and our results.
We will send you briefing slides on the trials and a link to forecast the outcomes, and a summary of the results.
We will keep your participation confidential.